<code id='149A1AD37E'></code><style id='149A1AD37E'></style>
    • <acronym id='149A1AD37E'></acronym>
      <center id='149A1AD37E'><center id='149A1AD37E'><tfoot id='149A1AD37E'></tfoot></center><abbr id='149A1AD37E'><dir id='149A1AD37E'><tfoot id='149A1AD37E'></tfoot><noframes id='149A1AD37E'>

    • <optgroup id='149A1AD37E'><strike id='149A1AD37E'><sup id='149A1AD37E'></sup></strike><code id='149A1AD37E'></code></optgroup>
        1. <b id='149A1AD37E'><label id='149A1AD37E'><select id='149A1AD37E'><dt id='149A1AD37E'><span id='149A1AD37E'></span></dt></select></label></b><u id='149A1AD37E'></u>
          <i id='149A1AD37E'><strike id='149A1AD37E'><tt id='149A1AD37E'><pre id='149A1AD37E'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:fashion    - browse:25477
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia